Effect Of Pimavanserin On Anxious Depression In Patients With Major Depression And An Inadequate Response To Previous Therapy: Secondary Analysis Of The Clarity Study

In a post hoc analysis, the effect of pimavanserin on anxious depression was determined from CLARITY, a randomized, double-blind, placebo-controlled study in patients with major depression and an inadequate response to previous therapy. Patients were randomized in a 3:1 ratio to placebo or pimavanserin 34 mg daily added to ongoing antidepressant therapy. At 5 weeks, placebo nonresponders were rerandomized to placebo or pimavanserin for an additional 5 weeks. Mean change from baseline to week 5 for the Hamilton depression rating scale (HAMD) anxiety/somatization (AS) factor was examined for all patients and those with a score >= 7 at baseline. Least squares (LS) mean [standard error (SE)] difference between placebo and pimavanserin for the AS factor score was -1.5 (0.41) [95% confidence interval (CI) -2.4 to -0.7;P= 0.0003; effect size: 0.634]. Among patients with an AS factor score >= 7 at baseline, LS mean (SE) difference was -2.2 (0.66) (95% CI -3.5 to -0.9;P= 0.0013; effect size: 0.781). Response rates (>= 50% reduction in HAMD-17 from baseline) were 22.4 and 55.2% (P= 0.0012) and remission rates (HAMD-17 total score <7) were 5.3 and 24.1% (P= 0.0047), respectively, with placebo and pimavanserin among patients with a baseline AS factor score >= 7. Among patients with anxious major depressive disorder at baseline, adjunctive pimavanserin was associated with a significant improvement.